# 2025-08149: FDA Classifies STI Detection Device for Quicker Patient Access

2025-08149, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s), is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08149
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08149
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s)
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19631
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

FDA Classifies STI Detection Device for Quicker Patient Access

## Summary

The FDA is officially classifying devices that detect DNA from non-viral germs causing sexually transmitted infections (STIs) and their resistance markers as Class II, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps companies bring these important tests to patients faster and safer, starting May 9, 2025. Labs, device makers, and patients will all benefit from quicker access to innovative STI testing without extra red tape.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections and associated resistance marker(s) into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections and associated resistance marker(s)'s classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Faster Access to STI DNA Tests: benefit, medium. The FDA officially classifies tests that detect DNA from non-viral germs causing sexually transmitted infections and their resistance markers as Class II with special controls, effective May 9, 2025 (classification was applicable January 23, 2019). The agency says this classification reduces regula…
- Enables 510(k) Predicate Use: benefit, medium. When FDA classifies this device type via De Novo, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of premarket approval. The final order codifies the device type into 21 CFR 866.3393 and notes the device is subject t…
- Labeling Must Warn About Test Limits: benefit, low. The device labeling must include statements that a negative test does not rule out infection, results should be interpreted with other clinical data, and detection of resistance markers does not prove antibiotic susceptibility. The special controls (21 CFR 866.3393(b)(3)(iv) and (b)(3)(v)) spell ou…
- Sample-Collection Devices Must Be Cleared: cost, medium. Any sample collection device used with these tests must be FDA-cleared, -approved, or -classified as 510(k) exempt for the claimed specimen types, or must be cleared in the premarket submission as part of the test. This requirement is set out in the special controls at 21 CFR 866.3393(b)(2).
- Clinical Study and Documentation Requirements: cost, high. The special controls require detailed design verification and validation, including analytical studies and clinical study results with prospective samples for each claimed specimen type, a predefined statistical analysis plan, and documentation of software impacts (21 CFR 866.3393(b)(4) and (3)(iii…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08149 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08149/medical-devices-immunology-and-microbiology-devices-classification-of-the-device-to-detect-nucleic)
- [2025-08149 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08149.pdf)

## Related
- [Previous: 2025-08148, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classifica…](https://policyrisk.com/federal-register/2025-08148)
- [Next: 2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08150)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08149 (as of 2026-10-16).
